Coherus BioSciences, Inc. (NASDAQ:CHRS) provider of late-stage clinical biologics platform will be discussing 3Q20 financial results with the investment community.on 5th November 2020 at 4:30 PM eastern time.
Those interested in listening to the conference call live via the Internet can visit www.coherus.com
Earnings Expectation
Coherus BioSciences, Inc. provider of late-stage clinical biologics platform, is reporting third quarter earnings results on Thursday 5th November 2020, after market close.
The consensus estimates from Thomson Reuters are income of $ 0.41 per share from $ 122.88 million in revenue. For the full year, analysts predict revenues of $ 494.57 million, while looking forward to income of $ 1.92 per share.
Coherus BioSciences, Inc., a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the bodys ability to fight infections. The company sells UDENYCA in the United States.
